A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
This will be a double-blind, placebo-controlled, study using daily doses of up to 24 mg/ day
Galantamine HBr in the treatment of adults who meet DSM-IV criteria for childhood-onset ADHD.
Specific hypotheses are as follows:
Hypothesis 1: ADHD symptomatology in adults with DSM-IV ADHD will be responsive to acute
Galantamine HBr treatment.
Hypothesis 2: Galantamine HBr -associated improvement in ADHD symptomatology in adults will
translate into improved functional capacities (neuropsychological, social, and occupational)
as well as an increased quality of life throughout acute treatment.
Hypothesis 3: Galantamine HBr treatment will be safe and well tolerated as reflected by a low
drop out rate and absence of major differences from placebo.